# reload+after+2024-01-21 04:46:17.562818
address1§320 Hatch Drive
city§Foster City
state§CA
zip§94404
country§United States
phone§415-851-2410
website§https://www.notablelabs.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Matthew De Silva', 'title': 'Founder & Executive Chairman', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas A. Bock M.B.A., M.D.', 'title': 'CEO & Director', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joseph P. Wagner Ph.D.', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§103.86138
currency§USD
dateShortInterest§1702598400
forwardEps§-1.6
exchange§NCM
quoteType§EQUITY
shortName§Notable Labs, Ltd.
longName§Notable Labs, Ltd.
firstTradeDateEpochUtc§1412170200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9e25d101-7671-335a-b328-0a6fce687c00
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§9.0
targetMeanPrice§9.0
targetMedianPrice§9.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.301
grossMargins§0.76154
ebitdaMargins§0.0
trailingPegRatio§None
